Advertisement
Advertise here Publish your press releases here Sponsor BioPortfolio
Follow us on Twitter Sign up for daily news and research emails Contributors wanted

Gene therapy as future treatment of erectile dysfunction.

04:45 EDT 25th April 2014 | BioPortfolio

Summary of "Gene therapy as future treatment of erectile dysfunction."

Importance of the field: Erectile dysfunction (ED) is a major men's health problem. Although the high success rate of treating ED by phosphodiesterase 5 (PDE5) inhibitors has been reported, there are a significant number of ED patients who do not respond to currently available treatment modalities. Areas covered in this review: To elucidate the current status of gene therapy applications for ED, gene therapy approaches for ED treatment are reviewed. What the reader will gain: Gene therapy strategies that can enhance nitric oxide (NO) production or NO-mediated signaling pathways, growth factor-mediated nerve regeneration or K(+) channel activity in the smooth muscle could be promising approaches for the treatment of ED. Although the majority of gene therapy studies are still in the preclinical phase, the first clinical trial using non-viral gene transfer of Ca(2+)-activated, large-conductance K(+) channels into the corpus cavernosum of ED patients showed positive results. Take home message: Gene therapy represents an exciting future treatment option for ED, especially for people with severe ED unresponsive to current first-line therapies such as PDE5 inhibitors although the long-term safety of both viral and non-viral gene therapies should be established.

Affiliation

University of Pittsburgh School of Medicine, Department of Urology, Suite 700 Kaufmann Medical Building, 3471 Fifth Avenue, Pittsburgh, PA 15213, USA +1 412 692 4137 ; +1 412 692 4380 ; nyos@pitt.edu.

Journal Details

This article was published in the following journal.

Name: Expert opinion on biological therapy
ISSN: 1744-7682
Pages:

Links

PubMed Articles [28729 Associated PubMed Articles listed on BioPortfolio]

All Men with Vasculogenic Erectile Dysfunction Require a Cardiovascular Workup.

An association between erectile dysfunction and cardiovascular disease has long been recognized, and studies suggest that erectile dysfunction is an independent marker of cardiovascular disease risk....

New advances in erectile technology.

New discoveries and technological advances in medicine are rapid. The role of technology in the treatment of erectile dysfunction (ED) will be widened and more options will be available in the years t...

Low-Intensity Shock Wave Therapy and Its Application to Erectile Dysfunction.

Although phosphodiesterase type 5 inhibitors (PDE5Is) are a revolution in the treatment of erectile dysfunction (ED) and have been marketed since 1998, they cannot restore pathological changes in the...

Cardiometabolic risk factors in patients with erectile dysfunction.

Introduction. There is an increasing interest in the association between erectile dysfunction (ED) and cardiovascular risk factor. Epicardial adipose tissue (EAT) is associated with insulin resistance...

Testosterone Replacement Therapy: Should It Be Performed in Erectile Dysfunction?

The classical etiology of erectile dysfunction (ED) comprises aging and vascular, neurogenic, psychological and hormonal components. Recent studies have shown that ED can be the forerunner of serious...

Clinical Trials [3705 Associated Clinical Trials listed on BioPortfolio]

Extracorporeal Shock Wave Therapy for the Treatment of Erectile Dysfunction

Low intensity shockwaves have been proven in animal studies to induce local growth of new blood vessels from existing ones. The hypothesis of this study is that shockwave therapy could im...

Treatment of Erectile Dysfunction II

Randomized, placebo-controlled, double-blind, parallel design, Phase 3 study to evaluate the safety and efficacy of udenafil, an orally administered, potent and selective inhibitor of PDE-...

Treatment of Erectile Dysfunction I

Randomized, placebo-controlled, double-blind, parallel design, Phase 3 study to evaluate the safety and efficacy of udenafil, an orally administered, potent and selective inhibitor of PDE-...

Investigate the Responsiveness of the Erectile Quality Scale to Vardenafil Flexible Dose vs Placebo in Males With Erectile Dysfunction (ED)

This study was conducted to evaluate in adult men with erectile dysfunction (often called impotence), the effect of vardenafil HCl on the quality of their erections. Many men experience oc...

The Incidence and Treatment of Insulin Resistance Among Men With Erectile Dysfunction

Determine if men with erectile dysfunction (ED) are more likely to have insulin resistance compared to healthy controls.

Medical and Biotech [MESH] Definitions

Surgical insertion of cylindric hydraulic devices for the treatment of organic ERECTILE DYSFUNCTION.

The inability in the male to have a PENILE ERECTION due to psychological or organ dysfunction.

A plant alkaloid with alpha-2-adrenergic blocking activity. Yohimbine has been used as a mydriatic and in the treatment of ERECTILE DYSFUNCTION. It is also alleged to be an aphrodisiac.

Inability to achieve and maintain an erection (ERECTILE DYSFUNCTION) due to defects in the arterial blood flow to the PENIS, defect in venous occlusive function allowing blood drainage (leakage) from the erectile tissue (corpus cavernosum penis), or both.

Rigid, semi-rigid, or inflatable cylindric hydraulic devices, with either combined or separate reservoir and pumping systems, implanted for the surgical treatment of organic ERECTILE DYSFUNCTION.

Search BioPortfolio: